Experiments in cells and mice suggest that fat-derived asprosin can promote mitochondrial damage and senescence in vascular lining cells, identifying a possible molecular link between aging adipose tissue and vascular dysfunction.
Fat tissue is not simply an energy store. It is an endocrine organ whose secreted signals can reach distant tissues, including the endothelial cells lining blood vessels. New preclinical findings place one such signal, asprosin, upstream of mitochondrial damage, inflammatory signaling and cellular senescence in the vascular wall.
A report on the preclinical findings describes experiments in cultured human endothelial cells and several mouse models. Asprosin exposure reproduced some vascular and inflammatory changes induced by D-galactose, an experimental model used to accelerate aging-like stress in mice. An anti-asprosin antibody and genetic loss of asprosin reduced several of those changes.
The specific primary paper described in the report is not identifiable in the available peer-reviewed record. Its exact results should therefore be treated as reported preclinical findings rather than independently verified evidence. However, published studies provide relevant support for key parts of the proposed biological pathway.
A signal from fat reaches the vessel wall
The reported experiments approach the asprosin hypothesis from several directions. In mice exposed to D-galactose, treatment with an anti-asprosin antibody reduced measured senescence markers and inflammatory cytokines. Mice injected with asprosin developed broadly similar elevations in those markers, along with thicker vessel walls and higher systolic blood pressure.
Genetic evidence pointed in the same direction. Mice unable to produce asprosin showed less inflammation, vascular-wall thickening and collagen accumulation after D-galactose exposure than mice that could still make the protein. Using both an antibody and genetic deletion is valuable in a preclinical study because agreement between distinct interventions makes it less likely that a result depends on one experimental tool alone.
The protection was not complete. The antibody did not correct the impaired vascular dilation caused by D-galactose, indicating that asprosin is unlikely to account for every component of the induced phenotype. D-galactose also creates an accelerated stress model rather than reproducing the full complexity of natural aging.
Experiments with adipocyte-conditioned medium offered a more direct test of communication between fat cells and the endothelium. Medium collected from adipocytes unable to produce asprosin had less damaging effects on cultured human endothelial cells: it blunted senescence induced by hydrogen peroxide and better preserved cell proliferation and migration. These cell experiments connect the proposed source of the signal to its vascular target, although they cannot show how much asprosin reaches blood vessels in a living person.
Mitochondrial DNA may act as the alarm
The proposed mechanism begins with mitochondrial stress. In cultured endothelial cells, asprosin reportedly increased mitochondrial fragmentation, damaged mitochondrial membranes and promoted the escape of mitochondrial DNA into the cytoplasm. That location matters because DNA outside its usual cellular compartments can be interpreted as a danger signal.
The cGAS–STING pathway is one of the systems that detects misplaced DNA and initiates inflammatory responses. In the reported experiments, reducing STING activity prevented asprosin-induced senescence, placing the pathway downstream of mitochondrial damage. Increased mitochondrial reactive oxygen species appeared to contribute to this sequence.
Independent work supports the broader pathway, though not the complete claim that fat-derived asprosin initiates it during human aging. A 2024 mechanistic study of endothelial senescence found mitochondrial injury and mitochondrial DNA release into the cytoplasm in senescent endothelial cells. Endothelial-specific STING deficiency reduced senescence, inflammation, mitochondrial dysfunction and atherosclerosis in mice.
A separate study of disturbed blood flow and endothelial cells reached a related conclusion using a different trigger. Oscillatory shear stress caused mitochondrial DNA leakage and cGAS–STING activation in cultured endothelial cells and Apoe-deficient mice. Genetic loss or pharmacological inhibition of endothelial STING attenuated the associated senescence findings.
Together, these studies establish mitochondrial DNA leakage and STING signaling as a plausible route to endothelial senescence in cells and mice. They do not establish asprosin as the initiating signal in people; rather, they show that the downstream mechanism proposed for asprosin is already biologically credible under other forms of vascular stress.
Earlier evidence points to endothelial susceptibility
Asprosin has previously been tested directly on vascular cells. In a 2022 in-vitro study of human umbilical-vein endothelial cells, asprosin increased markers associated with endothelial-to-mesenchymal transition while reducing endothelial markers. In that process, endothelial cells lose aspects of their normal identity and acquire features associated with matrix-producing cells.
That experiment did not study aging in people, and endothelial-to-mesenchymal transition is not equivalent to cellular senescence. It nevertheless shows that cultured human endothelial cells can respond adversely to asprosin, providing a separate line of evidence that the protein may affect vascular-cell state.
The distinction between these evidence types is important. Cultured cells are useful for mapping molecular steps. Mouse interventions can test whether changing a target alters a whole-organism phenotype. Neither establishes that the same exposure, effect size or treatment response occurs in humans. The current evidence does not show that blocking asprosin improves vascular function or clinical outcomes in people.
A research target upstream of vascular inflammation
Asprosin is scientifically interesting because it may connect two features of aging biology that are often studied separately: changes in adipose-tissue signaling and declining vascular-cell function. If it sits upstream of mitochondrial DNA leakage and STING activation, it could offer researchers a way to intervene before a broader inflammatory program is engaged.
The reported antibody and knockout findings also make asprosin more than a passive marker within these models. Lowering or eliminating it changed several measured outcomes, while adding it reproduced part of the induced phenotype. That pattern supports a causal role under the experimental conditions, although reduced senescence markers should not be interpreted as vascular rejuvenation or evidence of longer life.
The most informative next work would establish whether the findings replicate in an accessible primary paper, test the mechanism during natural aging rather than only accelerated stress, and determine how circulating asprosin relates to adipose biology and endothelial function in humans. For now, the work defines a focused preclinical hypothesis: an adipose-derived protein may damage endothelial mitochondria, release mitochondrial DNA and activate a senescence-promoting inflammatory pathway.